In addition, MMP9 acts as a sheddase of HER2 [48], and an increase in circulating HER2 through shedding may be an essential factor in development of resistance to chemotherapy, including Ttzm resistance, in advanced breast cancer [49]. This evidence concerns the gene ERBB2 and breast carcinoma.